Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > REGULATORY
REGULATORY
- AbbVie’s Parkinson’s Drug, Kaken’s Eschar Remover Skip March Listing
March 9, 2023
- Chuikyo OKs Listing of Mounjaro, Libtayo, Imjudo; 30 Billion-Plus Peak Sales for Lilly Med
March 9, 2023
- Paxlovid Priced at 99,027 Yen per 5-Day Treatment; 5% Premium on Lagevrio Price
March 9, 2023
- Xocova Priced at 51,851 Yen per Course with Peak Sales Put at 19.2 Billion Yen
March 9, 2023
- Tagrisso Faces 10.5% Slash in June in Its Second Re-Pricing
March 9, 2023
- Emgality, Veklury, and More to Get Lower Prices in June: CEA Scheme
March 9, 2023
- LDP League Delivers Proposal on Health Coverage for Patches to Finance Minister
March 9, 2023
- Expert Narukawa Backs JPMA Pitch on Value-Based Pricing, but Disputes Blanket Price Maintenance for Patented Meds
March 8, 2023
- Japan Starts Omicron Vaccine Rollout for Ages 5-11
March 8, 2023
- Japan Panel OKs 2-Dose Regimen for Silgard 9 for Girls below Age 15
March 8, 2023
- AbbVie’s ADC Bags Sakigake Designation in Japan
March 8, 2023
- Japan Cabinet Approves Bill to Create “Japan CDC”
March 8, 2023
- Japan to Lead Discussions on AMR Measures at G7 Summit: PM
March 7, 2023
- Eli Lilly’s UC Drug Mirikizumab in Line for Approval as Early as March
March 6, 2023
- MHLW Calls for Fair-Price Distribution of Drugs Subject to Unprofitability Re-Pricing
March 6, 2023
- SCARDA to Invite Funding Applications for New Modality Research without Requiring PI Plans
March 3, 2023
- LDP Taskforce Begins Social Security Debates towards Honebuto
March 3, 2023
- MHLW Unveils New List Prices for FY2023 Revision, Ad-Hoc PMP Raise for 143 Products
March 3, 2023
- Komeito Petitions Govt for Market Incentives for Meiji’s Novel Antibacterial
March 2, 2023
- LDP League to Compile Final Proposal for SaMD Reimbursement This Spring
March 2, 2023
ページ
Japan’s pharmaceutical industry is undergoing a structural shift in its workforce, with the role of sales reps shrinking while production…
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…